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Abstract
The purpose of this study was to determine the effects of 6-OXO, a purported nutritional
aromatase inhibitor, in a dose dependent manner on body composition, serum hormone levels, and
clinical safety markers in resistance trained males. Sixteen males were supplemented with either
300 mg or 600 mg of 6-OXO in a double-blind manner for eight weeks. Blood and urine samples
were obtained at weeks 0, 1, 3, 8, and 11 (after a 3-week washout period). Blood samples were
analyzed for total testosterone (TT), free testosterone (FT), dihydrotestosterone (DHT),
estradiol, estriol, estrone, SHBG, leutinizing hormone (LH), follicle stimulating hormone (FSH),
growth hormone (GH), cortisol, FT/estradiol (T/E). Blood and urine were also analyzed for clinical
chemistry markers. Data were analyzed with two-way MANOVA. For all of the serum hormones,
there were no significant differences between groups (p > 0.05). Compared to baseline, free
testosterone underwent overall increases of 90% for 300 mg 6-OXO and 84% for 600 mg,
respectively (p < 0.05). DHT underwent significant overall increases (p < 0.05) of 192% and 265%
with 300 mg and 600 mg, respectively. T/E increased 53% and 67% for 300 mg and 600 mg 6-OXO,
respectively. For estrone, 300 mg produced an overall increase of 22%, whereas 600 mg caused a
52% increase (p < 0.05). Body composition did not change with supplementation (p > 0.05) and
clinical safety markers were not adversely affected with ingestion of either supplement dose (p >
0.05). While neither of the 6-OXO dosages appears to have any negative effects on clinical
chemistry markers, supplementation at a daily dosage of 300 mg and 600 mg for eight weeks did
not completely inhibit aromatase activity, yet significantly increased FT, DHT, and T/E.
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Background
Athletes have long been looking for a way to gain an edge
in competition, which has lead many to turn to anabolic
steroids. Anabolic steroids are defined as testosterone
(TST) or derivatives of TST that are used for their ability to
create a state of nitrogen retention and increase fat-free
mass by stimulating protein synthesis and/or by decreas-
ing protein breakdown. It has been previously thought
that anabolic steroids did not cause an increase in muscle
size and strength, but now more recent studies have
shown the effect that supra-physiological levels of TST
and TST derivatives can increase muscle size and strength
in males [1-7].
Once produced, TST does not circulate freely in the blood.
Rather, total testosterone (TT) is almost 100% bound in
blood to proteins with 40% bound to albumin, 40%
bound to a β-globulin called sex hormone binding globu-
lin (SHBG), and 17% is bound to other proteins. The
small fraction of TST that is not bound is considered the
free testosterone (FT) and is the bioactive component of
the hormone. Once bound to its androgen receptor, TST
can also be converted to dihydrotestosterone (DHT) by
the enzyme 5-α reductase. Alternatively, TST can be con-
verted into estradiol through aromatization by the action
of the enzyme aromatase.
There are pro-hormone nutritional supplements availa-
ble, such as androstenedione, that are precursors to TST,
and designer androstenedione derivatives such as andros-
tenediol that are purported to support TST production.
These compounds are alleged to increase TST, or to
increase the concentration of compounds that can act like
TST. There are data in young men demonstrating that the
acute sublingual ingestion of androstenedione and
androstenediol increased FT and TT up to 180 min [8] and
240 min [9] after ingestion. However, these are acute stud-
ies with a small window of TST elevation and do not rele-
vantly reflect the manner in which these types of
supplements are typically utilized. More appropriately,
there are studies demonstrating that the daily oral inges-
tion of these compounds over the course of several weeks,
in conjunction with resistance training [10,11] and other-
wise [12] to be ineffective at increasing endogenous TST
levels.
However, in the continued attempts to find supplements
that elevate testosterone levels, some companies are man-
ufacturing compounds that have no apparent androgenic
activity, but are targeted at increasing the endogenous lev-
els of TST by blunting aromatization and subsequent
estrogen synthesis. Aromatase inhibiting drugs are not
new and have been used for years as a method of prevent-
ing and treating various types of cancer. The drugs operate
by suppressing estrogen levels and subsequently increas-
ing endogenous free testosterone levels [increased free tes-
tosterone/estrogen (T/E) ratio] and the effects of various
pharmacologic aromatase inhibitors such as anastrozole
and exemestane on the T/E in both young and old men are
well documented [13-15].
Nutritional supplements designed with the intent of
inhibiting aromatase activity are relatively new to the fit-
ness community. Examples of these supplements are 6-
OXO and Novedex XT, and are alleged to act similar to
such aromatase inhibiting drugs as formestane. We have
recently shown that eight weeks of supplementation with
the aromatase inhibiting nutritional supplement Novedex
XT (hydroxyandrost-4-ene-6,17-dioxo-3-THP ether and
3,17-diketo-androst-1,4,6-triene) was effective at increas-
ing serum testosterone and DHT, while only displaying
slight increases in estrogen levels in young, eugonadal
men [16]. Additionally, compounds with the same
(androst-4-ene-3,6,17-trione) and very similar (androst-
5-ene-4,7,17-trione) structure as 6-OXO have been shown
to irreversibly bind to the aromatase enzyme thereby caus-
ing a decrease in estradiol production [17,18]. Therefore,
use of these aromatase-inhibiting compounds seem to
decrease aromatization and subsequent estradiol synthe-
sis, which apparently increases both TST and T/E.
In view of our previous work [16], there is still little data
available on the effects of the various nutritional aro-
matase inhibiting supplements. Therefore, the purpose of
the study was threefold and was to determine the efficacy
of an eight week oral supplementation period with either
300 mg/day or 600 mg/day of 6-OXO on: 1) serum hor-
mone levels, 2) serum and urinary clinical safety markers
and systemic hemodynamic effects, and 3) serum hor-
mone, serum and urinary clinical safety markers, and sys-
temic hemodynamic effects after a 3-week washout period
following both supplementation protocols.
Methodology
Participants
Sixteen apparently healthy, recreationally-active males
with a mean age of 26.6 ± 4.9 years, height of 180.2 ± 6.3
cm, body fat of 14.9 ± 4.8 %, and body weight of 87.3 ±
13.2 kg served as participants in the study. All participants
were cleared for participation by passing a mandatory
medical screening. Participants with contraindications to
exercise as outlined by the American College of Sports
Medicine and/or who had consumed any nutritional sup-
plements (excluding multi-vitamins) such creatine mono-
hydrate or various androstenedione derivatives or
pharmacologic agents such as anabolic steroids two
months prior to the study were not allowed to participate.
All eligible subjects signed a university-approved
informed consent document. Additionally, all experimen-Journal of the International Society of Sports Nutrition 2007, 4:13 http://www.jissn.com/content/4/1/13
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tal procedures involved in this study conformed to the
ethical considerations of the Helsinki Code.
Testing sessions
Testing sessions were performed at week 0 and after weeks
1, 3, 8, and 11 in which blood and urine samples were
obtained and where body composition, serum hormones,
blood and urinary clinical safety markers, and systemic
hemodynamic safety markers were evaluated.
Body composition assessment
Total body mass (kg) was determined on a standard dual
beam balance scale (Detecto Bridgeview, IL). Percent
body fat, fat mass, and fat-free mass were determined
using DEXA (Hologic 4200 W, Waltham, MA). Quality
control calibration procedures were performed on a spine
phantom (Hologic X-CALIBER Model DPA/QDR-1
anthropometric spine phantom) and a density step cali-
bration phantom prior to each testing session. Total body
water and compartment-specific fluid volumes were
determined by bioelectric impedance analysis (Xitron
Technologies Inc., San Diego, CA).
Blood and urine collection
Venous blood samples were obtained from an antecubital
vein into a 10 ml collection tube. Blood samples were
allowed to stand at room temperature for 10 min and
then centrifuged. The serum was removed and frozen at -
80°C for later analysis. Urine samples were obtained in
mid-stream into a collection container using a standard
collection protocol. Urine samples were frozen at -80°C
for later analysis. Blood and urine samples were obtained
after a 12-hour fast and standardized to the same time of
day for each sample.
Supplementation protocol
Based on the premise that there were no muscle perform-
ance measurements to be made in the study, such as mus-
cle strength and power, that could otherwise generate a so-
called "placebo effect," the decision was made not to uti-
lize a placebo group. Participants were equally divided,
matched by age and body mass, and then randomly
assigned in double-blind fashion to an eight-week supple-
mentation protocol consisting of the daily oral ingestion
of either 300 mg or 600 mg of 6-OXO [androst-4-ene-
3,6,17-trione (ErgoPharm, Champaign, IL)]. For the 300
mg group, (n = 8; total body mass = 79.3 ± 13.2 kg, fat-free
mass = 67.1 ± 7.9 kg; body fat = 14.7 ± 5.4 %) 100 mg was
ingested in the morning with breakfast and 200 mg was
ingested with the evening meal. For the 600 mg group, (n
= 8; total body mass = 81.1 ± 13.3 kg, fat-free mass = 69.0
± 12.1 kg; body fat = 15.0 ± 4.2 %) 300 mg was ingested
in the morning with breakfast and 300 mg was ingested
with the evening meal. For days where no exercise
occurred, the supplements were ingested in the same
timely fashion. After the supplementation period, a three-
week washout period was required during which neither
supplement was ingested. Upon analysis of serum testo-
sterone from the baseline blood samples at week 0, it was
confirmed that all participants completing the study were
eugonadal [10–30 nmol/L (27–107 ng/ml)][19].
Physical activity, dietary intake records, and 
supplementation compliance
During both the supplementation and washout periods
the participants' physical activity and dietary intake were
not supervised; however, it was required that all partici-
pants keep detailed physical activity and dietary records
and not change their routine dietary habits or level of
physical activity throughout the course of the study. As
such, participants were required to keep weekly physical
activity records and four-day dietary records during weeks
0, 1, 3, 8, and 11 and turn in their physical activity and
dietary records during each testing session. Each partici-
pant returned all of their dietary and physical activity eval-
uations at the required time points for a 100%
compliance rate. The four-day dietary recalls were evalu-
ated with the Food Processor dietary assessment software
program (ESHA Research, Salem, OR) to determine the
average daily macronutrient consumption of fat, carbohy-
drate, and protein. In an effort to ensure compliance to
the supplementation protocol, participants were supplied
with the appropriate number of capsules to be ingested
during the time between testing sessions 1, 3, and 8. Upon
reporting to the lab at each of the respective testing ses-
sions, participants returned the empty containers and a
capsule count was performed if necessary.
Reported side effects from supplements
At the last four testing sessions, participants reported by
questionnaire whether they tolerated the supplement,
supplementation protocol, as well as report any medical
problems/symptoms they may have encountered
throughout the study.
Hemodynamic clinical safety markers
At each testing session, participants assumed a supine
position for 15 minutes and had their heart rate (HR),
systolic blood pressure (SBP), and diastolic blood pres-
sure (DBP) determined to assess the hemodynamic safety
of supplementation with 6-OXO. Heart rate was deter-
mined by use of a Polar heart rate monitor (Polar, San
Ramon, CA), and blood pressure was assessed with a mer-
curial sphygmomanometer using standard procedures.
Blood and urinary clinical markers
The serum clinical chemistry variables glucose, total pro-
tein, blood urea nitrogen, creatinine, BUN/creatinine
ratio, uric acid, AST, ALT, CK, LDH, GGT, albumin, glob-
ulin, sodium, chloride, calcium, carbon dioxide, totalJournal of the International Society of Sports Nutrition 2007, 4:13 http://www.jissn.com/content/4/1/13
Page 4 of 10
(page number not for citation purposes)
bilirubin, alkaline phosphatase, triglycerides, cholesterol,
HDL, and LDL were determined with a Dade Dimension
RXL clinical chemistry analyzer (Dade-Behring, Inc.,
Newark, DE). The whole blood hematological variables,
hemoglobin, hematocrit, red blood cell counts, MCV,
MCH, MCHC, RDW, neutrophils, lymphocytes, mono-
cytes, eosinophils, and basophils, were determined with
an Abbott Cell Dyne 3500 hematology analyzer (Abbott
Laboratories, Chicago, IL). The urinary variables glucose,
ketones, blood, protein, nitrite, bilirubin, leukocyctes,
specific gravity, pH, urobilinogen were analyzed with a
Bayer Clinitek 200 Plus urine analyzer (Bayer Diagnostics,
Tarrytown, NY).
Serum hormones
Serum TT, FT, DHT, estradiol, estrone, estriol, SHBG, LH,
growth hormone (GH), cortisol (Diagnostics Systems
Laboratories, Webster, TX), and FSH (Alpco Diagnostics,
Windham, NH) using enzyme-linked immunoabsorbent
assays (ELISA) and enzyme-immunoabsorbent assays
(EIA) with a Wallac Victor-1420 microplate reader (Per-
kin-Elmer Life Sciences, Boston, MA), and the assays were
performed at a wavelength of either 450 or 405 nm,
respectively. The average specificity for all assays was 3.5
pg/ml, and in all cases the intra-assay and inter-assay var-
iances were < 10%. Additionally, the amount of cross-
reactivity between androstenedione and FT, TT, and DHT
was 0.06%, 0.09%, and 1.9%, respectively.
Statistical analysis
Due to the likelihood of the body composition, serum
hormones, and serum and urinary clinical chemistry
marker dependent variables being related to one another,
statistical analyses were performed by utilizing three sep-
arate repeated-measures two-factor [treatment groups (2)
× time point (5)] mixed methods multivariate analysis of
variance (MANOVA). The use of MANOVA also reduces
the risk of Type I errors, by controlling for alpha level that
could result with the use of repeated analyses of variance
(ANOVA). Box M tests were performed to test for differ-
ences in covariance matrices. Bartlett's Test of Sphericity
were performed to test that the variance and covariance
matrix of the dependent variables was circular in form
which would allow for accurate interpretation of univari-
ate ANOVAs. Levene's Test of Equality of Error was per-
formed to test for equality of variance for each dependent
variable. Further analysis of the main effects for Group
and Test were performed by separate one-way ANOVAs
and by using Sidak pair-wise comparisons. Significant
between-group differences were then determined by
employing the Tukey HSD Post Hoc Test when the vari-
ances were equal and a Games-Howell Post Hoc Test was
used when the variances were not equal. The changes
from post- to pre-training for each criterion variable were
then analyzed with a one-way ANOVA. Non-significant
trends (p < .10) were reported as partial Eta squared to
illustrate the effect size, where an effect size of 0.51 is rel-
atively strong, 0.24 is moderate and is 0.17 relatively weak
[20]. All statistical procedures were performed using SPSS
13.0 software and a probability level of < 0.05 was
adopted throughout.
Results
Physical activity and dietary intake records
All 16 participants appeared to have exhibited 100% com-
pliance with the supplement protocol, and were able to
complete the required dosing regimen and testing proce-
dures with no side effects from both the 300 mg and 600
mg doses of 6-OXO. In addition, subjective analysis of the
physical activity evaluations revealed that none of the par-
ticipants had any noticeable changes in their level of phys-
ical activity over 11-week period. There were no
significant differences between groups (p > 0.05) in total
daily caloric or macronutrient intake of carbohydrates,
protein, and fats over the course of the 11 weeks (data not
shown).
Body composition
Table 1 shows the measured mean ± SD values for the
body composition variables. The results revealed no sig-
nificant group × time interaction (p = 0.884) or main
effect for test (p = 0.581) or time (p = 0.748) indicating
that there were no significant differences in body compo-
sition values.
Table 1: Body Composition Variables
300 mg 600 mg
W e e k 0138 1 1 0138 1 1
ECF (L) 19.6 ± 2.5 19.9 ± 3.1 19.6 ± 2.4 19.5 ± 2.3 20.0 ± 2.5 19.8 ± 3.1 20.2 ± 3.3 20.0 ± 2.7 20.2 ± 3.3 21.2 ± 3.1
ICF (L) 30.0 ± 5.1 30.3 ± 5.3 30.0 ± 5.0 29.2 ± 4.2 29.9 ± 4.8 29.5 ± 6.2 29.7 ± 5.0 29.9 ± 4.5 30.6 ± 6.4 32.5 ± 5.8
TBW (L) 49.5 ± 7.4 50.2 ± 8.1 49.6 ± 7.2 48.7 ± 6.2 49.9 ± 7.0 49.3 ± 9.2 49.8 ± 8.2 49.9 ± 7.2 50.8 ± 9.6 53.6 ± 8.7
Fat Mass (kg) 12.2 ± 6.3 12.4 ± 6.2 12.5 ± 6.2 13.0 ± 5.5 13.0 ± 5.8 12.1 ± 3.5 12.5 ± 3.3 12.4 ± 3.5 12.1 ± 3.2 12.6 ± 3.4
Fat-Free Mass (kg) 64.5 ± 7.7 64.6 ± 8.0 64.1 ± 7.5 63.9 ± 8.7 64.0 ± 8.1 69.0 ± 12.1 68.9 ± 12.4 68.8 ± 11.1 69.9 ± 12.0 70.1 ± 13.2
Total Body Mass (kg) 79.3 ± 13.2 79.6 ± 13.7 79.3 ± 12.9 79.5 ± 13.0 78.8 ± 13.8 81.1 ± 13.3 81.5 ± 13.8 81.3 ± 12.8 82.0 ± 13.5 82.7 ± 14.7
Body Fat (%) 14.7 ± 5.4 14.9 ± 5.2 15.1 ± 5.3 15.9 ± 4.7 15.8 ± 4.9 15.0 ± 4.2 15.4 ± 4.0 15.3 ± 3.9 14.8 ± 3.6 15.3 ± 3.8
No significant differences in body composition were observed during the 11 weeks (p > 0.05).Journal of the International Society of Sports Nutrition 2007, 4:13 http://www.jissn.com/content/4/1/13
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Whole blood clinical safety markers
Table 2 shows the measured mean ± SD values for the
whole blood clinical chemistry markers. The results dem-
onstrated no significant group × time interaction (p =
0.829) or main effects for test (p = 0.567), indicating that
there were no significant differences in whole blood clin-
ical safety markers over the course of the study. However,
the results did show a significant main effect for group,
indicating that the 600 mg group had higher baselines val-
ues for hematocrit (p = 0.030), absolute monocytes (p =
0.027), and absolute basophils (p = 0.018) that persisted
throughout the study, and was apparently independent of
6-OXO supplementation.
Serum clinical safety markers
Table 3 shows the measured mean ± SD values for the
serum clinical chemistry markers. Results showed no sig-
nificant group × time interaction (p = 0.815) or main
effects for test (p = 0.671) indicating that there were no
significant differences in whole blood clinical safety mark-
ers over the course of the study. However, the results did
show significant main effects for group and revealed that
the 600 mg group was shown to have significantly higher
baseline values for total cholesterol (p = 0.02), low den-
sity lipoprotein (p = 0.01), blood urea nitrogen (p =
0.016), GGT, calcium, total blood protein, and albumin
(p = 0.01) that persisted throughout the study, and was
apparently independent of 6-OXO supplementation.
Urine clinical safety markers
Table 4 shows the measured mean ± SD values for the
urine clinical chemistry markers. The results revealed no
significant group × time interaction (p = 0.794) or main
effect for test (p = 0.543) or time (p = 0.693) indicating
that there were no significant differences in urine clinical
safety markers over the course of the study.
Hemodynamic clinical safety markers
Table 5 shows the measured mean ± SD values for the
hemodynamic clinical safety markers. There was no signif-
icant group × time interaction (p = 0.725) or main effect
for test (p = 0.583) demonstrating no significant differ-
ences in hemodynamic measures over the course of the
study. However, the results did show a significant main
effect for group and revealed that the 300 mg group had a
significantly higher baseline SBP (p = 0.041) that per-
sisted throughout the study, and was apparently inde-
pendent of 6-OXO supplementation.
Serum hormones
Table 6 shows the mean values ± SD for all the hormones
over the course of the study. There was no significant
group × test interaction (p = 0.882) for any of the hor-
mones measured (p = 0.882). However, there were signif-
icant main effects for group for SHBG (p = 0.022), LH (p
= 0.01), and FSH (p = 0.014) with a trend towards signif-
icance in cortisol (p = 0.053, effect size = 0.052). Pair-wise
comparisons indicated that the 600 mg group had lower
levels of SHBG and LH, and higher levels of FSH. These
differences existed at baseline and persisted throughout
the duration of the study and were, therefore, independ-
ent of 6-OXO supplementation.
There was a significant main effect for Test for FT (p =
0.017), DHT (p = 0.006), T/E (p = 0.025), and estrone (p
= 0.007), along with a trend for significance for TT (p =
0.062, effect size = 0.068). Compared to baseline, post-
hoc tests showed FT levels to be higher at week 1 (p =
0.016) and week 3 (p = 0.019), and week 8 (p = 0.037).
DHT levels were significantly higher at week 1 (p = 0.026),
week 3 (p = 0.004), and week 8 (p = 0.014). T/E levels
were significantly higher at week 1 (p = 0.034), week 3 (p
= 0.018), and week 8 (p = 0.37). Estrone was significantly
higher at week 1 (p = 0.003) and week 3 (p = 0.007), with
a trend towards also being higher at week 8 (p = 0.057,
effect size = 0.056).
Discussion
In this study, we sought to determine the effects of 6-OXO
supplementation provided at a daily dosage of 300 mg
and 600 mg for eight weeks on body composition, serum
hormones, and clinical safety markers. There were no
adverse side effects reported from the participants and no
significant changes in hemodynamic measures and in
clinical chemistry markers measured in whole blood,
serum, or urine during the course of the study suggesting
Table 2: Hemodynamic Safety Markers
300 mg 600 mg
W e e k 0 1 3 8 1 1 0138 1 1
Heart Rate (bpm) 64 ± 7.6 58 ± 4.7 61 ± 5.1 61 ± 5.6 64 ± 8.7 57 ± 6.2 58 ± 6.7 59 ± 7.2 61 ± 3.0 64 ± 8.6
SBP (mmHg) 116 ± 13.0* 114 ± 9.8* 117 ± 12.3* 117 ± 10.7* 116 ± 8.8* 75 ± 8.7 74 ± 9.3 73 ± 8.1 70 ± 7.9 77 ± 5.6
BBP (mmHg) 109 ± 6.4 107 ± 5.2 113 ± 6.9 115 ± 11.4 114 ± 4.8 69 ± 8.2 74 ± 4.5 71 ± 9.4 76 ± 9.9 74 ± 6.3
* Denotes significant main effects for groups (p < 0.05). Results indicated that the 300 mg group had significant higher baseline values that persisted 
throughout the study, and was apparently independent of 6-OXO supplementation.Journal of the International Society of Sports Nutrition 2007, 4:13 http://www.jissn.com/content/4/1/13
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that 6-OXO at the dosages investigated for a period of
eight weeks appears safe within the confines of the mark-
ers assessed.
In regard to body composition, neither dose of 6-OXO
demonstrated any significant improvement in fat mass or
fat-free mass over the course of the study. Even with signif-
icant increases in FT and DHT, this furthers indicates that
6-OXO supplemented at these dosages for eight weeks did
not decrease fat mass or cause an anabolic response by
increasing muscle mass. Increased serum androgens levels
have been shown to stimulate lipolysis due to increases in
the activity of hormone sensitive lipase [21]; however, rel-
ative to the dosage and/or the duration of ingestion of 6-
OXO on serum androgens in the present study, neither
had any effect on body composition. In our previous
study, eight weeks of supplementation with 72 mg/day of
the nutritional aromatase inhibitor Novedex XT had no
effect on fat-free mass, but was effective at producing a
modest, but significant 3.5% decrease in fat mass when
compared to placebo [16].
For the serum hormones, the only significant changes that
occurred over the course of the study that were 6-OXO
dependent were for FT, DHT, estrone, and T/E. FT and
DHT underwent overall increases of 90% and 192% for
300 mg 6-OXO and 84% and 265% for 600 mg, respec-
tively, while T/E increased 53% and 67% for 300 mg and
600 mg 6-OXO, respectively. However, for FT, DHT, and
T/E there were no significant differences between groups,
suggesting 300 mg and 600 mg of 6-OXO to be equally as
effective in increasing androgen levels. In addition, by the
end of the three-week washout period, the levels of these
hormones (and all others) had returned to normal levels.
The FT, DHT, and T/E data is in agreement with previous
research, which showed an increase in TT with ingestion
of an aromatase inhibitor [19,22,23], with 6-OXO
(unpublished data) [24], and with our previous study
with Novedex XT where we showed average increases of
283%, 625%, and 566% for TT, FT, and DHT [16]. Rela-
tive to the ability of 6-OXO to inhibit aromatization by
way of our serum hormone markers, estrone underwent
overall increases of 22% and 52% for 300 mg and 600 mg,
respectively, and estradiol underwent overall increases of
27% and 12% for 300 mg and 600 mg, respectively. These
data indicate that aromatase activity was not completely
inhibited by 6-OXO throughout the eight-week period.
It seems logical that DHT concentration would increase
concomitantly with elevations in TST because DHT is a
TST metabolite. Relative to the change in FT and the sig-
nificant increases in DHT over the eight-week period, the
present data suggest a role for 6-OXO in up-regulating the
activity of the 5α-reductase enzyme. Unlike TST, DHT is a
non-aromatizable androgen [13]. Because 6-OXO is a
type I steroidal aromatase inhibitor, it is assumed that this
supplement would completely inhibit aromatase activity,
thereby leading to elevations in endogenous TST. How-
ever, our results suggest the contrary; 6-OXO does elevate
TST and DHT levels without the complete inhibition of
serum aromatase activity. As a result, it is conceivable that
the apparent TST aromatization occurring was in part
responsible for the observed elevations in estradiol and
estrone. Aromatase catalyzes the conversion of TST to
estradiol, of androstenedione to estrone, and of 16α-
hydroxylated dehydroepiandrosterone to estriol [25]. The
purported mechanism for an increase in TST with aro-
matase inhibition has been reported as a decrease in estra-
diol levels that leads to feedback to the hypothalamus to
stimulate TST-induced increases in estradiol [26,27]. This
Table 3: Whole Blood Clinical Chemistry Markers
300 mg 600 mg
Week 0 1 3 8 11 0 1 3 8 11
WBC (K/µL) 5.3 ± 1.6 5.0 ± 1.1 5.3 ± 1.7 5.2 ± 2.0 4.5 ± 1.5 5.5 ± .96 4.6 ± .91 5.0 ± 1.0 4.9 ± .67 5.1 ± .84
RBC (M/µL) 5.0 ± .51 5.0 ± .50 4.6 ± .84 5.0 ± .37 4.9 ± .46 5.2 ± .37 5.1 ± .33 5.2 ± .24 4.9 ± 1.2 5.3 ± .30
Hemoglobin (g/dL) 15 ± 1.1 15 ± 1.1 15 ± 1.2 15 ± .59 15 ± 1.0 15 ± .95 15 ± .93 15 ± .63 15 ± .66 15 ± .78
Hematocrit (%) 44 ± 3.5 44 ± 3.7 44 ± 3.6 45 ± 2.4 43 ± 3.3 46 ± 3.0* 44 ± 2.3* 45 ± 1.9* 46 ± 2.1* 46 ± 2.7*
MCV (fL) 88 ± 2.8 88 ± 2.8 88 ± 2.4 89 ± 2.4 89 ± 2.9 87 ± 2.7 86 ± 2.8 87 ± 2.6 87 ± 2.3 87 ± 2.5
MCH (pg) 30 ± 1.2 30 ± 1.3 30 ± 1.0 30 ± 1.3 30 ± 1.0 29 ± 1.0 29 ± .95 29 ± .98 29 ± 1.1 29 ± .78
MCHC (g/dL) 34 ± .69 34 ± .76 34 ± .64 33 ± .78 34 ± .81 33 ± .60 34 ± .85 33 ± .56 33 ± .61 34 ± .60
Neutrophils 2.9 ± 1.0 2.5 ± .43 2.9 ± 1.1 2.8 ± 1.0 2.3 ± 1.1 2.8 ± .52 2.4 ± .47 2.6 ± .66 2.5 ± .29 2.9 ± 1.1
Lymphocytes 1.7 ± .51 1.9 ± .84 1.7 ± .62 1.8 ± .87 1.6 ± .69 2.0 ± .39 1.6 ± .39 1.8 ± .50 1.7 ± .44 1.8 ± .44
Monocytes .45 ± .12 .39 ± .12 .44 ± .12 .36 ± .07 .37 ± .14 .43 ± .14* .38 ± .04* .39 ± .13* .40 ± .09* .44 ± .12*
Eosinophils .12 ± .06 .13 ± .08 .11 ± .05 .12 ± .06 .12 ± .06 .14 ± .08 .14 ± .09 .16 ± .10 .16 ± .09 .16 ± .07
Basophils .06 ± .02 .05 ± .01 .05 ± .01 .05 ± .01 .05 ± .02 .07 ± .02* .06 ± .02* .07 ± .02* .07 ± .01* .06 ± .01*
* Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines values that persisted throughout the 
study, and was apparently independent of 6-OXO supplementation.J
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Table 4: Serum Clinical Chemistry Markers
300 mg 600 mg
W e e k 0138 1 10 1 3 81 1
Triglyceride (mg/dl) 86.8 ± 29.5 98.5 ± 46.1 105.3 ± 29.5 110.3 ± 58.8 85.9 ± 41.9 117.5 ± 60.2 115.5 ± 50.5 116.6 ± 40.5 110.9 ± 43.4 97.8 ± 36.1
Cholesterol (mg/dl) 177.0 ± 38.2 182.1 ± 26.1 173.9 ± 32.2 175.0 ± 22.6 166.1 ± 20.7 194.6 ± 24.9* 185.1 ± 22.3* 201.1 ± 20.8* 201.6 ± 37.8* 199.5 ± 31.0*
HDL (mg/dL) 50.1 ± 12.5 51.3 ± 10.9 53.6 ± 17.6 49.4 ± 7.9 48.3 ± 8.9 53.0 ± 4.7 53.8 ± 9.8 58.5 ± 11.9 53.9 ± 18.7 57.0 ± 18.3
LDL (mg/dL) 107.9 ± 26.9 112.0 ± 18.8 105.4 ± 23.5 104.4 ± 22.8 100.6 ± 16.8 115.9 ± 21.5* 111.4 ± 21.7* 124.8 ± 22.0* 127.1 ± 33.5* 121.4 ± 25.2*
GGT (U/L) 23.9 ± 5.7 23.8 ± 4.6 23.1 ± 4.8 27.3 ± 7.9 26.0 ± 7.0 32.3 ± 9.6* 33.6 ± 11.2* 33.6 ± 7.8* 38.8 ± 11.8* 36.4 ± 8.3*
LDH (U/L) 127.0 ± 19.4 130.6 ± 23.3 125.4 ± 19.6 114.5 ± 25.8 130.0 ± 33.0 125.5 ± 17.4 128.0 ± 18.0 132.8 ± 23.4 132.1 ± 24.6 140.6 ± 32.6
Uric Acid (g/dl) 6.1 ± 1.7 5.8 ± 1.1 5.7 ± 0.9 5.2 ± 1.0 5.5 ± 1.4 6.1 ± 1.3 6.1 ± 1.6 6.5 ± 1.2 5.7 ± 1.0 5.7 ± 1.3
Glucose mg/dl 94.5 ± 9.4 95.8 ± 10.3 97.6 ± 10.4 94.0 ± 8.2 93.9 ± 9.6 95.1 ± 8.4 94.3 ± 6.5 100.5 ± 6.1 105.1 ± 17.1 89.9 ± 14.8
BUN (mg/dL) 16.9 ± 2.9 19.4 ± 5.0 20.6 ± 4.5 18.5 ± 3.0 19.4 ± 3.6 21.1 ± 7.6* 22.3 ± 5.1* 22.5 ± 3.8* 19.8 ± 3.5* 21.3 ± 2.4*
Creatinine (mg/dl) 1.4 ± 0.1 1.4 ± 0.2 1.4 ± 0.2 1.3 ± 0.2 1.3 ± 0.3 1.4 ± 0.2 1.4 ± 0.2 1.5 ± 0.2 1.5 ± 0.2 1.3 ± 0.3
Calcium (mg/dl) 12.5 ± 1.7 14.2 ± 3.2 14.8 ± 3.0 14.9 ± 2.1 15.2 ± 3.4 15.6 ± 4.4* 16.4 ± 3.4* 14.9 ± 2.8* 13.7 ± 2.6* 17.0 ± 3.0*
Total Protein g/dL 9.8 ± 0.5 9.9 ± 0.4 9.9 ± 0.6 9.8 ± 0.5 9.5 ± 0.4 10.1 ± 0.6* 10.1 ± 0.7* 10.8 ± 0.7* 10.4 ± 0.7* 10.2 ± 0.9*
Albumin g/dL 7.4 ± 0.6 7.7 ± 0.4 7.8 ± 0.6 7.4 ± 0.5 7.3 ± 0.5 7.9 ± 0.9* 8.0 ± 0.9* 8.5 ± 1.0* 8.3 ± 0.9* 8.1 ± 0.9*
Total Bilirubin (mg/dl) 4.7 ± 0.5 4.8 ± 0.4 4.9 ± 0.5 4.6 ± 0.5 4.6 ± 0.3 5.0 ± 0.5 5.1 ± 0.5 5.4 ± 0.6 5.3 ± 0.6 5.1 ± 0.6
ALP (U/L) 0.8 ± 0.3 0.8 ± 0.6 1.0 ± 0.4 0.9 ± 0.5 0.9 ± 0.6 0.6 ± 0.3 0.6 ± 0.2 0.9 ± 0.4 0.8 ± 0.3 0.8 ± 0.2
AST (U/L) 73.9 ± 13.3 76.3 ± 12.1 73.1 ± 12.8 70.5 ± 15.7 64.0 ± 19.9 77.1 ± 21.3 76.1 ± 21.0 79.5 ± 19.4 76.4 ± 19.0 63.1 ± 27.8
ALT (U/L) 24.4 ± 9.6 24.5 ± 9.3 21.3 ± 6.8 18.3 ± 6.6 30.3 ± 25.1 22.6 ± 6.5 27.3 ± 5.5 30.0 ± 11.7 24.5 ± 8.0 26.3 ± 10.0
CK (U/L) 28.6 ± 11.5 25.6 ± 5.5 22.4 ± 7.2 28.4 ± 10.8 27.1 ± 5.5 28.1 ± 14.2 25.0 ± 7.2 23.8 ± 6.7 28.9 ± 15.6 32.6 ± 10.7
* Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines that persisted throughout the study, and was apparently independent of 6-OXO 
supplementation.J
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) Table 5: Urine Clinical Safety Markers
300 mg 600 mg
W e e k 0138 1 1 0138 1 1
Glucose 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Ketones 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Blood 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Protein 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Nitrite 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Bilirubin 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Leukocytes 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Specific Gravity 1.02 ± 0.01 1.02 ± 0.01 1.01 ± 0.01 1.02 ± 0.01 1.02 ± 0.01 1.02 ± 0.01 1.02 ± 0.01 1.02 ± 0.01 1.02 ± 0.01 1.02 ± 0.01
pH 5.5 ± 0.76 5.6 ± 0.58 5.9 ± 0.90 5.4 ± 0.68 5.3 ± 0.53 5.8 ± 1.13 5.8 ± 1.13 5.8 ± 1.13 5.8 ± 1.13 5.8 ± 1.13
Urobilinogen (E.U./dl) 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
No significant differences were observed (p > 0.05). A zero reading indicates that there were no traceable amounts of markers present. Readings that were above a zero 
reading indicated a trace amount and are otherwise indicated by numbers 1, 2, and 3.
Table 6: Serum Hormone Levels
300 mg 600 mg
W e e k 0 13 8 1 1 01 38 1 1
TT (ng/ml) 4.7 ± 2.1 6.2 ± 1.4 5.6 ± 2.0 5.8 ± 2.1 5.0 ± 1.0 3.9 ± 1.2 5.6 ± 1.5 5.8 ± 1.3 5.4 ± 1.9 6.29 ± 5.0
‡ FT (pg/ml) 17.2 ± 8.8 37.1 ± 33.03* 30.13 ± 17.3* 30.5 ± 16.9* 18.2 ± 10.6 22.7 ± 13.0 39.2 ± 13.2* 45.1 ± 27.0* 40.6 ± 36.1* 22.4 ± 9.8
‡ DHT (ng/mL) 0.9 ± 0.4 3.1 ± 1.8* 2.8 ± 1.4* 2.4 ± 1.3* 1.0 ± 0.3 0.9 ± 0.2 3.0 ± 1.3* 4.4 ± 3.8* 2.8 ± 1.7* 1.7 ± 1.2
Estradiol (ng/mL) 89.6 ± 86.2 112.3 ± 124.2 121.2 ± 125.6 107.1 ± 106.6 101.8 ± 103.8 69.1 ± 23.6 71.4 ± 35.9 85.5 ± 49.4 75.8 ± 47.9 78.3 ± 54.5
‡ Estriol (pg/ml) 0.04 ± 0.03 0.04 ± 0.04 0.05 ± 0.07 0.05 ± 0.06 0.06 ± 0.05 0.03 ± 0.04 0.04 ± 0.05 0.04 ± 0.03 0.05 ± 0.03 0.04 ± 0.02
‡ T/E 0.2 ± 0.1 0.3 ± 0.3* 0.3 ± 0.1* 0.3 ± 0.2* 0.2 ± 0.1 0.3 ± 0.2 0.6 ± 0.4* 0.5 ± 0.1* 0.5 ± 0.5* 0.3 ± 0.2
Estrone (pg/ml) 334.1 ± 89.5 428.8 ± 122.* 400.9 ± 135.4* 397.2 ± 166.0* 323.5 ± 89.3 268.8 ± 43.7 425.3 ± 137.0* 431.7 ± 141.6* 365.6 ± 92.0* 308.8 ± 101.6
† SHBG (nmol/L) 128.9 ± 36.6 135.7 ± 33.5 127.4 ± 37.3 137.0 ± 42.5 132.5 ± 43.5 130.6 ± 26.6* 119.5 ± 32.6* 106.9 ± 17.6* 101.4 ± 29.5* 112.9 ± 35.8*
†LH (mIU/ml) 6.6 ± 4.2 8.9 ± 5.6 6.0 ± 3.2 6.3 ± 3.0 5.4 ± 2.4 3.2 ± 1.8* 4.5 ± 2.1* 4.3 ± 1.9* 4.1 ± 2.6* 3.9 ± 2.6*
† FSH (mIU/ml) 0.03 ± 0.04 0.04 ± 0.06 0.03 ± 0.03 0.06 ± 0.06 0.03 ± 0.05 0.1 ± 0.2* 0.09 ± 0.3* 0.03 ± 0.07* 0.08 ± 0.2* 0.2 ± 0.4*
Cortisol (µg/dl) 23.0 ± 7.1 24.3 ± 7.3 23.6 ± 4.1 19.5 ± 8.9 22.4 ± 5.0 24.5 ± 6.5 25.4 ± 4.1 25.5 ± 3.6 26.3 ± 8.1 24.9 ± 4.9
GH (pg/ml) 46.9 ± 9.7 59.7 ± 150.7 62.4 ± 44.1 82.2 ± 64.2 107.6 ± 284.4 56.8 ± 114.1 49.7 ± 72.1 119.4 ± 306.2 63.4 ± 43.7 165.8 ± 254.1
† Significant main effect for Group (p < 0.05). ‡ Significant main effect for Test (p < 0.05). * Significantly different from baseline (Week 0) (p < 0.05).Journal of the International Society of Sports Nutrition 2007, 4:13 http://www.jissn.com/content/4/1/13
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would infer that in order for an increase in TST to occur, a
decrease in estradiol would have to be seen, and this is not
what happened in this study.
Regarding SHBG, the levels did not change over the course
of the study. This suggests that the effects of 6-OXO on FT
to be somewhat independent of the circulating levels of
SHBG since at least 95% of circulating testosterone is
bound to SHBG at any one time. Interestingly, however,
the 600 mg group had lower SHBG concentrations at
baseline and throughout the course of the study suggest-
ing this to be independent of the specific dose of 6-OXO.
The results of this study indicate that eight weeks of 6-
OXO supplementation had no effect on body composi-
tion or clinical safety markers, but incompletely inhibited
aromatase activity and significantly increased endogenous
DHT levels that were attenuated after a three-week wash-
out period. Therefore, while neither of the 6-OXO dosages
appears to have any negative effects on clinical chemistry
markers, supplementation at a daily dosage of 300 mg
and 600 mg for eight weeks did not completely inhibit
aromatase activity, yet significantly increased FT, DHT,
and T/E.
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